2009年09月-2012年06月，四川大学华西药学院，药剂学，硕士；

2012年09月-2015年06月，四川大学生物治疗国家重点实验室,化学生物学，博士；

2015年07月-2019年03月，电子科技大学附属医院·四川省人民医院，助理研究员；

2015年10月-2018年12月，四川大学，生物学，博士后（在职）；

2017年01月-2021年10月，电子科技大学医学院，讲师；

2019年04月-至今，电子科技大学附属医院·四川省人民医院，副研究员；

2021年11月-至今，电子科技大学医学院，副教授；

2022年06月-2023年05月，瑞典乌普萨拉大学访问学者。

第二届中国药理学会治疗药物监测研究专委会青委会委员

第一届四川省抗癌协会肿瘤临床药学专委会委员

第一届四川省药理学学会治疗药物监测研究专委会委员兼秘书

第十四批四川省卫健委学术技术带头人后备人选

作为项目负责人主持国家自然科学基金1项，中国博士后面上基金1项，四川省科技厅科研项目2项，省卫健委科研课题1项，电子科技大学中央高校基金1项，医院青年人才基金1项，吴阶平医学基金会等横向课题2项。

作为项目完成人获2017年四川省医学会医学科技一等奖1项，2020年四川省医学会医学科技二等奖1项。

发表学术论文40余篇，其中，以第一作者或通讯作者发表SCI论文10余篇。以排名第一的身份申请发明专利1项。

1. Yue Tong, et al.  Photocatalytic redox-neutral arylation of cyclopropanols  with cyanoarenes via radicalmediated C–C and C–CN bond cleavage.  Org. Chem. Front., 2022, 9: 2129-2134. (通讯作者)

2. Zhong Lei, et al. Small  molecules in targeted cancer therapy: advances, challenges, and future  perspectives. SIGNAL TRANSDUCTION AND TARGETED THERAPY,2021,6(1): 201.

3. Xuerun Peng, et al. Targeting  H3K36 methyltransferases NSDs: a promising strategy for tumor targeted  therapy.SIGNAL TRANSDUCTION AND TARGETED THERAPY,2021,6(1): 220. (通讯作者)

4. Zhenyu Yang, et al.  Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening  and activity evaluation. Bioorg Med Chem Lett, 2021,33: 127745. (通讯作者)

5. Lingyu Su, et al.  Anti-oral squamous cell carcinoma effects of a potent TAZ inhibitor AR-42.  Journal of Cancer, 2020, 11(2): 364-373. (通讯作者)

6. Qian Peng , et al.  Association of elevated Yes-associated protein expression with gastric cancer  and its clinicopathological features. J Biosci Med, 2020, 8, 96-109. (通讯作者)

7. Zhong Lei, et al.  Preclinical assessment of histone deacetylase inhibitor quisinostat as a  therapeutic agent against esophageal squamous cell carcinoma. Investigational  New Drugs, 2019, 37: 616-624.

8. Yanping Zhou, et al.  Design, synthesis and in vitro tumor cytotoxicity evaluation of  3,5-diamino-N-substituted benzamide derivatives as novel GSK-3β small molecule  inhibitors. Chem. Biodiversity, 2019, 16: e1900304. (通讯作者)

9. Yuxuan Zhu, et al. AR-42:  A pan-HDAC inhibitor with antitumor and antiangiogenic activities in  esophageal squamous cell carcinoma. DRUG DESIGN DEVELOPMENT AND  THERAPY,2019,13: 4321-4330.

10.Zhong Lei, et al.  Protective effect of ethyl vanillin against Aβ‑induced neurotoxicity in PC12  cells via the reduction of oxidative stress and apoptosis Experimental and  Therapeutic Medicine, 2019, 17: 2666-2674.

11.Zhong Lei, et al.  Relevance of methylenetetrahydrofolate reductase gene variants C677T and  A1298C with response to fluoropyrimidinebased chemotherapy in colorectal  cancer: a systematic review and meta-analysis. Oncotarget, 2018, 9 (58):  31291-31301.

12.Yang Ling-Ling#, Wang  Hua-Li#, Zhong Lei#, et al. X-ray crystal structure guided discovery of new  selective, substratemimicking sirtuin 2 inhibitors that exhibit activities  against non-small cell lung cancer cells. European Journal of Medicinal  Chemistry, 2018, 155: 806-823.

13.Zhong Lei, et al.  Relevance of MTHFR polymorphisms with response to floropyrimidine based  chemotherapy in oesophagogastric cancer: a meta-analysis. BMJ Open, 2018, 8:  e020767.

14.Zhong Lei, et al.  Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the  treatment of non-small cell lung cancer. Oncotarget, 2017, 8 (8):  12843-12854.  

15.Zhong Lei, et al. A  preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a  therapeutic agent against hepatocellular carcinoma. International Journal of  Cancer, 2014, 135 (12): 2972-2983.

16.Zhong Lei, Ma Chang-Ying, Zhang Hui, YangLi-Jun, Wan Hua-Lin, Xie Qing-Qing, Li Lin-Li, Yang Sheng-Yong*. A predictionmodel of substrates and non-substrates of breast cancer Resistance protein(BCRP) developed by GA–CG –SVM method. Computers in Biology and Medicine, 2011,41 (11): 1006-1013.